Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

419656

Sigma-Aldrich

N-Benzyl-2-nitro-1H-imidazole-1-acetamide

97%

Synonyma:

2-Nitro-N-(phenylmethyl)-1H-imidazole-1-acetamide, Benzonidazol, N-Benzyl-2-nitroimidazol-1-yl-acetamide

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen


About This Item

Empirický vzorec (Hillův zápis):
C12H12N4O3
Číslo CAS:
Molekulová hmotnost:
260.25
MDL number:
UNSPSC Code:
12352100
PubChem Substance ID:
NACRES:
NA.22

Quality Level

assay

97%

mp

189-192 °C (lit.)

solubility

methanol: soluble 50 mg/mL, clear, colorless to yellow

SMILES string

[O-][N+](=O)c1nccn1CC(=O)NCc2ccccc2

InChI

1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17)

InChI key

CULUWZNBISUWAS-UHFFFAOYSA-N

General description

N-Benzyl-2-nitro-1H-imidazole-1-acetamide (Benznidazole) is a nitro-heterocyclic compound. It is widely employed drug for the treatment of Chagas disease. It exhibits three polymorphic forms..

Application

N-Benzyl-2-nitro-1H-imidazole-1-acetamide (Benznidazole) may be used as reference drug for the extraction of guaianolide from the aerial parts of Tanacetum parthenium and to evaluate its in vitro antiprotozoal activity.

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves


Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

D E Perez-Mazliah et al.
The Journal of antimicrobial chemotherapy, 68(2), 424-437 (2012-10-30)
Even though the use of combined drugs has been proved to be effective in other chronic infections, assessment of combined treatment of antiparasitic drugs in human Chagas' disease has not been performed. Herein, a pilot study was conducted to evaluate
Israel Molina et al.
The New England journal of medicine, 370(20), 1899-1908 (2014-05-16)
Current therapeutic options for Chagas' disease are limited to benznidazole and nifurtimox, which have been associated with low cure rates in the chronic stage of the disease and which have considerable toxicity. Posaconazole has shown trypanocidal activity in murine models.
Alejandra B Ciccarelli et al.
Antimicrobial agents and chemotherapy, 56(10), 5315-5320 (2012-08-08)
A nutritional characteristic of trypanosomatid protozoa is that they need a heme compound as a growth factor. Because of the cytotoxic activity of heme and its structural similarity to cobalamins, we have investigated the in vitro and in vivo effect
Jean-Philippe Chippaux et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene, 107(1), 1-7 (2013-01-09)
A randomised, unblinded, clinical trial comparing two benznidazole regimens for congenital Chagas disease was carried out to determine whether simplification and reduction in the length of treatment could lead to better treatment compliance. This study was conducted in Santa Cruz
Glaucia Vilar-Pereira et al.
Brain, behavior, and immunity, 26(7), 1136-1149 (2012-07-31)
Inflammatory cytokines and microbe-borne immunostimulators have emerged as triggers of depressive behavior. Behavioral alterations affect patients chronically infected by the parasite Trypanosoma cruzi. We have previously shown that C3H/He mice present acute phase-restricted meningoencephalitis with persistent central nervous system (CNS)

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.